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Captopril and immune regulation. We examined the in vitro effect of
captopril (2.5 to 5 .sg/ml) on the primary antibody response of human B
cells. Captopril suppresses (by 50%) the specific anti-trinitrophenyl(TNP) response of unfractionated peripheral blood mononuclear cells
(PBM) but not that of nonadherent PBM. The susceptibility to captopril
suppression can be restored in the latter cell cultures by 10% adherent
radioresistant cells. This suppression is independent of prostaglandins.
In transfer experiments, cells preincubated with 5 g/ml captopril
suppress the antibody response of autologous nonadherent PBM. The
inductive phase of this suppression requires both adherent cells and
radiosensitive T cells. Once induced, the suppression can be transferred
by isolated T effector cells. In vivo after a unique oral intake of
captopril a moderate suppressor activity can be demonstrated in
adherent cells from normal individuals. We conclude that captopril
interferes with the immune regulation by inducing a suppressor circuit
involving monocytes and a T8 suppressor effector lymphocyte.
Le captopril et Ia regulation immune. Nous avons examine l'effet du
captopril (2,5 a 5 g/ml) sur Ia réponse anticorps primaire de cellules B
humaines. Le captopril supprime (de 50%) Ia réponse specifique anti-
trinitrophénol (TNP) de cellules mononuclées (PBM) non fractionnCes
mais non celles de PBM non-adherents. Dans les cultures de cellesci, Ia
susceptibilité a Ia suppression par le captopril peut être restaurée par
l'addition de 10% de cellules adhérentes radiorésistantes. Cette sup-
pression est indépendante des prostaglandines. Dans des experiences
de transfert, les cellules préincubees avec 5 g/ml de captopril suppri-
ment Ia réponse anticorps de PBM non-adherents autologues. L'induc-
tion de cette suppression nécessite a Ia fois des cellules adhérentes et
des cellules T radiosensibles. Une fois induite, Ia suppression est
transferable par des cellules T isolées. Aprés une prise orale unique de
captopril, les cellules adhérentes de volontaires normaux font preuve
d'une activitC suppressive modCrée. Ainsi, le captopril semble modifier
Ia regulation immune en induisant un circuit suppresseur qui fait
intervenir les monocytes et un effecteur de suppression de phenotype
18.
Captopril (Capoten®, Squibb Pharmaceutical Company, Par-
is, France), the first oral inhibitor of angiotensin-converting
enzyme (ACE), could have broadest indications than renin-
dependent hypertension, including some forms of essential
hypertension or cardiac congestive heart failure [1, 21. Howev-
er, this drug has serious side-effects in about 5% of long-term
treated patients, particularly in hypertensive patients with
impaired renal function, or those initially treated with a dose
higher than 400 mg/day [1]. The nature of these complications
as well as the possible occurrence of autoantibodies on treat-
ment suggests that captopril can interfere with immune regula-
tion. This is supported by recent investigations in animal
models [3, 4] and in vitro studies of human T cell proliferative
response [5, 6].
We analyzed the effect of captopril on the primary in vitro
antibody response of human peripheral blood mononuclear
(PBM) cells [7]. This model allows the analysis of cellular
interactions taking place in the differentiation of cells producing
specific 1gM. The B cell response is positively and negatively
regulated by T cells and monocytes [8, 9]. We show that
captopril induces a moderate transferable suppressor activity
which requires monocytes at the inductive phase and is mediat-
ed by the T8 lymphocyte subset.
Methods
In vitro antibody response. The in vitro antibody response
was induced and tested as previously described [7, 8]. Blood
was drawn from normal volunteers. Peripheral blood mononu-
clear cells (PBM) were separated and cultured at 2,5 x 106 cell
concentration in RPMI 1640 medium supplemented with 10%
fetal bovine serum in flat-bottomed wells (Costar 3524, Cam-
bridge, Massachusetts) (0.5 ml final volume). The antigen, a
trinitrophenyl conjugate of polyacrylamide (TNP-PAA) was
prepared and used as already described [7]. After 7 to 8 days
cells were collected and separated from the beads; the anti-TN P
response was measured by a Jerne-type plaque assay using
TNP-conjugated sheep red blood cells (TNP-SRBC) and uncon-
jugated SRBC as target erythrocytes. The response was ex-
pressed as the number of anti-TNP plaque-forming cells (PFC)
per 106 collected cells (PFC/l06). At least three cultures were
performed in each experimental group. The cell recovery and
viability were identical in the various experimental groups. In
each experiment, cultures without antigen were performed: The
background anti-TNP response was usually negative and never
exceeded 5% of the response of the stimulated cultures. Unless
otherwise stated, the results are the mean (± SE) responses
from different experiments involving different donors. The
Student's t test was used for statistical analysis. Captopril was
obtained from Squibb Laboratory, Paris, France (SQ 14 225, lot
no, 230002). It was dissolved in culture medium immediately
before use in the cultures.
The responding system. Two different preparations were
used as responding cells: unfractionated PBM isolated on
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Ficoll-Hypaque and non-adherent PBM, additionally filtered on
a nylon wool column [8, 9]. Nylon filtration resulted in a
decrease in the proportion of peroxydase (Pox) positive cells
from 15 to 30% to 3 to 5% without modification of the 1-B
lymphocyte ratio or of the T4 and T8 cell proportions [8].
Cell separations. In some experiments adherent cells were
isolated from unfractionated PBM by plastic adherence [9].
They contained at least 90% Pox positive cells.
T cells were separated from nonadherent PBM by E-rosette
formation using neuraminidase-treated SRBC. T cells contained
95% E-rosette forming cells. T cell subpopulations were isolat-
ed with an anti-T8 antibody OKT8 (Ortho Pharmaceutical
Corporation, Raritan, New Jersey). After incubation with OKT8
antibody, T5 and T8 cells were separated by the panning
technique [10]. The purity of these populations was assessed by
indirect fluorescence using OKT8 and OKT4 monoclonal anti-
bodies. T8 cells contained more than 95% OKT8 cells and
less than 5% OKT4 cells. T8 cells contained more than 90%
OKT4 cells and less than 5%OKT8 cells. They will be referred
to as T8 cells and T4 cells, respectively. In some experiments
cells were 2000 rd irradiated before culture.
Suppressor cell induction and assay. Suppressor cells were
induced as follows. Cells were incubated for 2 days alone
(control cells), with captopril (5 tg/ml) or with concanavalin A
(Con A, 2 gIml) as a positive control for suppression. After
incubation preincubated cells were washed with cs methyl
mannoside for Con A cells and added in a proportion of 10% to
cultures of autologous nonadherent PBM (responding cells).
The incubated cells were added to the responding cultures on
day 2 of the response according to the protocol we previously
described for Con A-induced suppressors [11]. The responding
cells were cultured alone (control response) or with the different
preincubated cells, and their anti-TNP response was measured
on day 7. To express the suppressive effect of the various
preincubated cells, the results are provided as the percent of the
control response in each experiment. The following prepara-
tions were preincuhated: unfractionated PBM, adherent cells, T
cells, adherent cells + T cells (20 to 80%, respectively). In some
experiments, preincubated adherent + T cells were separated at
the end of the incubation, in T8, T4 subsets.
Dosage of PGE2 production in cultures. Cultures of 5.106
unfractionated PBM were set up and at 48 hr the supernatants
were collected, and prostaglandin E2 (POE2) concentration was
measured by radioimmunoassay [9]. In four different experi-
ments endogenous POE2 production was evaluated in culture in
the presence or the absence of captopril (5 pg); no difference
was found: 378 62 nM POE2 in control cultures versus 356
50 in cultures with captopril.
In vivo drug intake. Five normal volunteers (having signed an
informed consent) absorbed 200 mg captopril orally. Blood was
drawn before and 90 mm after drug intake. At least I month
later the same protocol was performed with 160 mg propanolol.
Results
Adherent cell requirement for suppression by captopril. Cap-
topril when present in the culture medium at a 2.5 to 5 g/ml
concentration inhibits by 50% the in vitro antibody response
(Table I). This effect requires a threshold concentration of
monocytes. The response of unfractionated PBM is suppressed
whereas that of nonadherent PBM is unaffected. The addition of
Table 1. Adherent cell requirement for suppression of the antibody
response by captopril
Anti-TNP response
(PFC/106)
Without With
Cells in culture captopril captopril
Unfractionated 120 28 51 6 II <0.02
Nonadherentb 381 90 334 78 9 NS
Nonadherent +
adherent 292 68 133 37 9 <0.01
The culture contains 15 to 30% POX positive cells.
h The culture contains 3 to 5% pox positive cells.
The cultures have 10% adherent cells containing greater than 90%
POX positive cells.
10% adherent cells to nonadherent PBM cultures restores their
sensitivity to the inhibitory effect of captopril. A similar sup-
pression is observed when irradiated adherent cells are used (57
8% with adherent cells as compared to 54 3% with
irradiated adherent cells in three experiments). Captopril does
not modify the kinetics of the response in cultures of unfraction-
ated PBM. The response is suppressed by 46 15% on day 5,
by 64 5% on day 8, and by 57 5% on day 10 (three
experiments). The inhibition is observed only when captopril is
added during the first 24 hr of culture (results not shown).
Lack of prostaglandin involvement in the suppressive effect.
When indomethacin (3 X 10-6 M) is present in the culture
medium, a moderate (and nonstatistically significant) enhance-
ment of the response is observed: from 140 41 PFC/106 to 223
98 PFC/106 in seven experiments. However, the relative
suppression by captopril is not affected by indomethacin (50
5% as compared to 58 3% in control cultures). We verified
that captopril does not modify the in vitro production of POE2
by unfractionated PBM (see Methods). In addition the drug does
not increase the suppressive effect of exogeneous POE2 on the
in vitro antibody response, evaluated as previously described
19] (results not shown).
Transferable suppression induced by captopril. U nfraction-
ated PBM pretreated with 5 sg/m1 captopril can suppress the
response of autologous nonadherent PBM (Table 2). This
suppression is no longer observed when nonadherent PBM are
preincubated with captopril (see experiment 3). Thus in con-
trast with Con A-induced suppression, captopril-induced sup-
pression requires a threshold concentration of adherent cells at
the inductive phase.
Suppression by captopri!: interaction between a monocyte
and a suppressor T cell. To better characterize the cellular
interactions, we tested the ability of captopril and Con A to
generate a suppressor activity in cultures of isolated T cells or
of T cells cocultured with 20% adherent cells (Fig. I). Con A-
activated T cells were fully suppressive whereas in the case of
captopril only the combination of T cells and adherent cells
exerted a suppressive effect. Irradiation of T cells before the
preculture period abolished both suppressions.
Additional experiments were performed to define the nature
of the effector suppressor cell. Upon recovery of captopril,
incubated cells (adherent cells + T cells) were either transferred
to responding cultures or submitted to an additional separation
step. Nonadherent cells were separated into T4 and T8 cells
Number of
experiments P value
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Table 2. The suppression by captopril is transferable by
unfractionated PBM
Nature of incubated cells
Anti-TNP response of responding
cultures in the presence of cells
incubatedb with
Expt no. 0 Con A Captopril
Unfractionated 1 91 16 36
Unfractionated 2 74 — 10
Unfractionated 3 420 20 113
Nonadherent 3 309 64 418
The anti-TNP response is expressed as PFC/106 collected cells.
Unfractionated or nonadherent cells were cultured for 2 days, alone
or with Con A (2 gIml) or captopril (5 zg/ml), then washed, and added
to cultures of fresh autologous nonadherent PBM, the anti-TNP re-
sponse of which is provided.
(Fig. 2). Upon Con A activation both T4 and T8 cells were
suppressive (P < 0.05). In contrast, on preculture with captopril
only T8 cells exerted a suppressor effect (P < 0.00 1).
In vivo effect of capropril in normal subjects. Five normal
volunteers received 200 mg captopril orally. Their PBM were
isolated from blood drawn before (control cells) and 90 mm
after (treated cells) drug intake. The responses were identical in
cultures of control or treated nonadherent PBM (195 46
PFC/l06 and 168 33 PFC/l06, respectively). To test the
hypothesis that the adherent cell was involved in the initiation
of the suppression, we compared the effect of 10% control or
treated adherent cells on the response of control nonadherent
cells (Fig. 3A). In four patients a clearcut suppressive effect was
observed after captopril intake. As a mean, treated adherent
cells significantly suppressed the response (by 58 7%; P <
0.002) whereas control adherent cells did not exert a significant
suppression (by 24 18%).
As a control, the same five volunteers received 160 mg
propanolol at least 1 month later, and the same experiments
were performed (Fig. 3B). The in vitro response of their
nonadherent cells was comparable (220 41 PFC/106) and was
not significantly suppressed by either control or treated adher-
ent cells (by 18 8 and 24 8%, respectively).
Discussion
Adverse reactions occurred during long-term treatment by
captopril with a relatively high frequency in patients with renal
failure or treated with high dose protocol [1]. The nature of
these side effects (leucopenia adenopathies, membranous gb-
merulonephritis, and serum sickness-like syndrome), the occur-
rence of autoantibodies suggested an immunological mecha-
nism [12—15]. It is thus of interest to analyze the possible
interaction of this drug with the immune regulation. As reported
by other investigators who used T cell proliferation assays [5,
61, we observed that captopril can suppress the primary in vitro
antibody response of human PBM. This effect is obtained with
concentrations of 2.5 to 5 .tgIml, which is slightly above the
serum levels found in patients treated with moderate doses of
the drug [16]. We took advantage of the fact that the human B
cell response involves the interaction of various immunocompe-
tent cells to analyze the mechanism of this suppression.
The effect of captopril on the in vitro antibody response
riii
Adherent T cells Adherent + T Adherent + T0
Fig. 1. The induction of the suppression by captopril requires an
adherent cell and a radiosensitive T cell. Anti-TNP response (% of
control) in three experiments (mean sa) of nonadherent PBM
responding cultures in the presence of 10% preincubated cells of four
different preparations included: adherent cells, T cells, adherent cells +
T cells or adherent cells + irradiated T cells (adherent + T0); preincu-
bated cells were pretreated with: control medium, 1; Con A, or
captopril, . The a represents P < 0.02 as compared to the appropriate
control group. The anti-TNP response of control cultures (receiving no
incubated cells) was 245 158 PFC/106 in these three experiments.
Fig. 2. The effector of captopril-induced suppression: a T8 cell. Anti-
TNP response (% of control) in three experiments (mean SE) of
nonadherent PBM responding cultures, with 10% preincubated cells,
was observed. Adherent cells + T cells were preincubated with control
medium, Con A or captopril, •. The following preincubated cells
were transferred: adherent + T; T, or T8 (see Methods). This group of
cells was compared with the respective control group: a, P < 0.05; b, P
< 0.001; c, nonsignificant. The anti-TNP response of control cultures
(receiving no incubated cells) was 806 352 PFC/l06 in these three
experiments.
depends on the percentage of monocytes present in the culture.
The anti-TNP response can be induced in cultures of unfrac-
tionated PBM (containing 15 to 30% monocytes) or in cultures
of nonadherent PBM (containing 3 to 5% monocytes) [81. The
latter preparations contain enough monocytes to support the B
cell response, which is depressed only when less than 1%
monocytes are left. Both the responses of unfractionated and
nonadherent PBM are T dependent [7, 81 requiring a radioresis-
tant T cell, localized in the T4 subpopulation [171. We show that
captopril suppresses only the response of unfractionated PBM
or that of nonadherent PBM supplemented with 10% mono-
cytes. The monocytic nature of these latter cells is indicated by
the following properties: they are adherent, radioresistant, and
90% peroxydase positive.
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Fig. 3. In vivo effect of Captopril. Anti-TNP response (PFC/106) of
nonadherent PBM responding cultures from five normal individuals
(mean SE) cocultured with autologous adherent cells collected before
or 90 mm after the intake of 200 mg captopril (A) or 160 mg propanolol
(B). The intake of the drugs was separated by at least I month in each
subject.
This suggested that captopril does not directly suppress the B
cell response but induces a suppressor phenomenon. Indeed,
pretreatment of unfractionated PBM (but not of nonadherent
PBM) with the same concentration of captopril induces a
transferable suppression. This suppression can be induced in
cultures of T cells provided monocytes are present. The two
activities are clearly separated as the suppressor T cells are
radiosensitive. Cell separation experiments showed that the
effector of the suppression is in the T8 subpopulation, The
suppressor cells induced by captopril differed from those in-
duced by the T cell mitogen Con A at least in two respects: The
monocyte requirement was not apparent in our conditions for
Con A suppression; the effectors of Con A suppression belong
to the T8 and the T4 subsets, which agrees with the report of
Thomas et al [18]. We did not investigate the inductive phase of
the suppression induced in vitro by captopril. However, the fact
that adherent cells collected after an intake of captopril are
suppressive suggests that monocytes can initiate a suppressor
circuit when transferred in vitro. They could be the target of
captopril.
The latter results are indicative of an in vivo relevance for our
in vitro findings. Indeed both human and animal studies show
that captopril can suppress the immune and inflammatory
responses [3—61. Several mechanisms can be discussed for this
effect: (I) An interaction with prostaglandins which can modu-
late the immune response [19] was suggested by two in vivo
studies [5, 20]. However, we found no argument in favor of a
role of prostaglandins in the in vitro effect of captopril. (2) Two
elements may suggest that, regardless of its effect on the kinin-
prostaglandin pathway, captopril action on the ACE activity
could be implicated in its immunological effects. The anti-
inflammatory effect of captopril in vivo is correlated with the
decrease in ACE activity [3, 4]. Human monocytic cells which
seem to be responsible for the initiation of the in vitro suppres-
sion (this study) are ACE producers in normal subjects and in
sarcoidosis [21]; this production is influenced by T cells [22]. (3)
Conversely, the immunological effects of captopril may be
unrelated to its activity on ACE. In this respect they can be
compared with those reported for D-penicillamine. These drugs
have a strikingly similar chemical structure and comparable
side-effects. The immunosuppressive action of D-penicillamine
was established in animal and human studies [23]. However, D-
penicillamine suppresses human B cell response through a
negative effect on T helper cell function [23]. It will be of
interest to compare the occurrence of side-effects with new
inhibitors of ACE activity devoid of a sulfhydryl radical [24]
and to determine whether they can interfere with immune
regulation.
Our results provide new data on the mechanism of the effect
of captopril on the immune system. The suppressor circuit we
have defined in vitro may be determinant in the anti-inflamma-
tory effect of this drug [3, 4]. The possible role of such a circuit
in the occurrence of autoimmune or hypersensitivity phenome-
na is more difficult to determine. In vitro immunoregulatory
effects of the drugs that have the capacity to induce the
production of autoantibodies are variable [25—28]. The anoma-
lies induced by captopril could be one aspect of a more general
dysregulation of the immune response as described with other
drugs, which could favor an abnormal response in otherwise
susceptible individuals [29, 30]. Recently, the potential impor-
tance of autoanti-idiotypic antibodies in the maintenance of
self-tolerance have been outlined [31]. Captopril-induced sup-
pressor T cells could preferentially interfere with such a circuit,
thus leading to the occurrence of autoantibodies, particularly in
hypertensive patients [32]. Alternatively, these suppressor cells
could contribute to the clinical tolerance to the drug. Predis-
posed individuals could develop a sensitization to the captopril
molecule as described in the case of D-penicillamine. Such a
sensitization would lead to the clinical occurrence of side-
effects mediated by immune complexes in those subjects con-
comitant presenting a deficit in suppressor cell function. Such
defects have been implicated in the pathogeny of autoimmune
diseases [33, 34].
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